Bone Mineral Density Studies
Customize your policy alerts
Sign up for Aspirus Arise Policy CP-AMCR24-006A alerts
Get alerted when Policy CP-AMCR24-006A changes without checking for updates manually.
Monitor payer policy activity
Defines covered methods and coverage criteria for bone mineral density testing (e.g., DXA, SEXA, QCT) for Aspirus Medicare Advantage products and explains frequency and medical necessity considerations.
No material clinical or coverage changes in this revision.
Coverage Criteria for Bone Mineral Density Testing
inv-01: Medicare-covered indications
Medicare (Part B) covers BMD testing without cost share when any one of the following conditions is met:
Coverage generally allowed once every 2 years; may be covered more frequently when medically necessary (e.g., monitoring during long‑term glucocorticoid therapy or obtaining a baseline for future monitoring).
inv-15: Medicare-covered indications for BMD testing — 1 top-level node
May be covered more frequently when medically necessary (for example, during prolonged glucocorticoid therapy or to establish a baseline for monitoring).
inv-02: Not covered preventive uses
Not covered as preventive service:
These uses are listed as not covered as preventive service; diagnostic coverage may apply under other benefit categories.
Tests administered purely as preventive screening in individuals who have no documented risk factors and no history of fractures are explicitly excluded from preventive coverage. These preventive exclusions mean the service is not reimbursed under the preventive benefit category; diagnostic coverage may still be available if medical necessity is established under other benefit rules.
Routine screening in asymptomatic individuals without risk factors is not covered as a preventive service. Such testing may be considered not medically necessary under the preventive benefit and is therefore subject to denial unless a covered diagnostic indication or other benefit category supports payment.
Coding and Frequency
| 76977 | Ultrasound bone density measurement and interpretation, peripheral site(s), any method |
| 77078 | Computed tomography, bone mineral density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine) |
| 77080 | Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine) |
| 77081 | Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; appendicular skeleton (peripheral) (eg, radius, wrist, heel) |
| 77085 | Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine), including vertebral fracture assessment |
| G0130 | Single energy x-ray absorptiometry (sexa) bone density study, 1 or more sites, appendicular skeleton (peripheral) (e.g., radius, wrist, heel) |
Provider Actions and Documentation
Document Medicare-covered indication on the chart
Ensure clinical documentation supports one or more Medicare-covered indications before ordering BMD testing; include the specific indication in the medical record.
- Medicare-covered indications include: estrogen deficiency with clinical osteoporosis risk; vertebral abnormalities; anticipated or ongoing glucocorticoid therapy >3 months; primary hyperparathyroidism; monitoring response to FDA‑approved osteoporosis drug therapy.
Indication documentation required
Documentation should support one or more Medicare-covered indications (examples provided) or other medically necessary rationale for more frequent testing.
- Examples: estrogen deficiency with clinical osteoporosis risk; vertebral abnormalities; glucocorticoid therapy >3 months; primary hyperparathyroidism; monitoring FDA‑approved osteoporosis drug therapy.
- Aspirus may approve testing more frequently than every 2 years when medically necessary (e.g., long‑term glucocorticoid therapy or baseline for future monitoring).
Denial risk for low‑risk screening
Testing performed purely as preventive screening in individuals without risk factors or a history of fractures is not covered as a preventive service and may be denied.
- Routine screening in asymptomatic individuals without risk factors may be considered not medically necessary under the preventive benefit.
- Diagnostic coverage may still apply under other benefit categories if clinical indications are present.
Definitions of BMD Modalities
Frequency Limits for BMD Testing
Prior Authorization
Contrast Rules for BMD Modalities
No contrast rules for BMD studies
No contrast-related rules are provided for bone mineral density modalities.
Background
Bone mineral density studies measure mineral content of bone to diagnose osteoporosis, assess fracture risk, and monitor response to therapy. Common clinical uses include evaluation of individuals with established risk factors or prior fractures and monitoring therapy response; by contrast, testing performed solely for routine screening in people without risk factors is excluded from preventive coverage.
Not Covered
Preventive BMD testing in individuals without risk factors or a history of fractures is not covered under the preventive benefit. The policy lists these tests among services not covered as preventive care; diagnostic coverage may apply only when documentation supports a covered clinical indication or medical necessity.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.